Phase 2 study of temozolomide and Caelyx in patients with recurrent glioblastoma multiforme

Authors:

Abstract
Temozolomide has established activity in the treatment of recurrent glioblastoma multiforme (GBM). Caelyx (liposomal doxorubicin) has established act

This publication has 27 references indexed in Scilit: